Quarterly report pursuant to Section 13 or 15(d)

Fair Value (Details)

v3.21.2
Fair Value (Details)
 3 Months Ended 6 Months Ended
Oct. 04, 2019
USD ($)
Jul. 03, 2021
USD ($)
Jun. 27, 2020
USD ($)
Jul. 03, 2021
USD ($)
Jun. 27, 2020
USD ($)
reporting_unit
Dec. 31, 2020
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis            
Selling, general and administrative expense   $ 21,315,000 $ 32,904,000 $ 45,100,000 $ 61,771,000  
Number of reporting units impaired | reporting_unit         4  
Right-of-use asset impairment   0 0 0 $ 691,000  
Aerospace Segment            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis            
Impairment loss     $ 12,600,000   86,300,000  
AeroSat            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis            
Right-of-use asset impairment         $ 700,000  
Diagnosys            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis            
Cash paid to acquire stock $ 7,000,000.0          
Fair value of contingent consideration 2,500,000 0   0   $ 2,200,000
Potential additional earn-out $ 13,000,000.0          
Achievement period 3 years          
Earn-out achievement benchmark $ 72,000,000.0          
Selling, general and administrative expense   $ 2,200,000   $ 2,200,000